- Merck KGaA ( OTCPK:MKKGY ) has brokered a licensing agreement with Nerviano Medical Sciences gaining access to NMS-293, a next-generation highly selective and brain-penetrant PARP1 inhibitor.
- NMS-293 is currently in phase 1 as monotherapy for BRCA-mediated tumors and in combination with temozolomide for recurrent glioblastoma.
- Terms call for Merck KGaA ( OTCPK:MKGAF ) to pay Nerviano up-front and option exercise fees of up to $65M, as well as potential development and commercial milestone payments. Merck ( OTCPK:MKKGY ) has exclusive rights to manufacture, and commercialize NMS-293.
- In late August, Guardant Health ( GH ) expanded an existing agreement with Merck KGaA ( OTCPK:MKGAF ) on the development of precision cancer therapeutics .
For further details see:
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor